PE20230165A1 - Inhibidores de sarm1 - Google Patents
Inhibidores de sarm1Info
- Publication number
- PE20230165A1 PE20230165A1 PE2022001414A PE2022001414A PE20230165A1 PE 20230165 A1 PE20230165 A1 PE 20230165A1 PE 2022001414 A PE2022001414 A PE 2022001414A PE 2022001414 A PE2022001414 A PE 2022001414A PE 20230165 A1 PE20230165 A1 PE 20230165A1
- Authority
- PE
- Peru
- Prior art keywords
- halogen
- compound
- membered heteroaryl
- neuropathy
- chemotherapy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente descripcion proporciona un compuesto de formula (I); en donde A es un heteroarilo de 5 a 6 miembros con 1-3 heteroatomos seleccionados de O, N y S; R1 es un heterociclico saturado o parcialmente insaturado de 3 a 7 miembros o o un heteroarilo de 5 a 6 miembros; cada Rx se selecciona de halogeno, ciano, OR, SR, N(R)2, entre otros; R es H, un grupo alifatico C1-6, entre otros; L es una cadena alifatica C1-4 en donde uno o dos atomos de carbono se reemplazan opcionalmente por -S(O)2N(R)-, -N(R)S(O)2-, entre otros, opcionalmente sustituida; R2 es hidrogeno, halogeno, N(R)2, entre otros. Tambien refiere a una composicion farmaceutica que los comprende. Dicho compuesto es un inhibidor de SARM1; siendo util para tratar y/o prevenir la neurodegeneracion (por ejemplo, para reducir la degeneracion axonal) y/o una enfermedad o trastorno seleccionado de esclerosis lateral amiotrofica, esclerosis multiple, neuropatia periferica diabetica y neuropatia inducida por quimioterapia.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062958178P | 2020-01-07 | 2020-01-07 | |
US202063065736P | 2020-08-14 | 2020-08-14 | |
PCT/US2021/012333 WO2021142006A1 (en) | 2020-01-07 | 2021-01-06 | Inhibitors of sarm1 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20230165A1 true PE20230165A1 (es) | 2023-02-01 |
Family
ID=74505335
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2022001414A PE20230165A1 (es) | 2020-01-07 | 2021-01-06 | Inhibidores de sarm1 |
Country Status (19)
Country | Link |
---|---|
US (1) | US20230008433A1 (es) |
EP (1) | EP4087838A1 (es) |
JP (1) | JP7490781B2 (es) |
KR (1) | KR20220164471A (es) |
CN (1) | CN115175900A (es) |
AU (2) | AU2021206651B2 (es) |
BR (1) | BR112022013388A2 (es) |
CA (1) | CA3163265A1 (es) |
CL (1) | CL2022001825A1 (es) |
CO (1) | CO2022009514A2 (es) |
CR (1) | CR20220375A (es) |
DO (1) | DOP2022000141A (es) |
EC (1) | ECSP22053394A (es) |
IL (1) | IL294507A (es) |
JO (1) | JOP20220167A1 (es) |
MX (1) | MX2022008395A (es) |
PE (1) | PE20230165A1 (es) |
TW (1) | TW202140437A (es) |
WO (1) | WO2021142006A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20230339913A1 (en) | 2020-08-04 | 2023-10-26 | Nura Bio, Inc. | Substituted pyridine derivatives as sarm1 inhibitors |
US11945796B2 (en) | 2020-09-16 | 2024-04-02 | Nura Bio, Inc. | Substituted pyridine derivatives as SARM1 inhibitors |
KR20240041987A (ko) | 2021-07-28 | 2024-04-01 | 누라 바이오, 인크. | Sarm1 억제제로서 치환된 피리딘 유도체 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6787555B2 (en) * | 2001-04-30 | 2004-09-07 | The Procter & Gamble Company | Triazole compounds useful in treating diseases associated with unwanted cytokine activity |
DE60332475D1 (de) * | 2002-10-30 | 2010-06-17 | Vertex Pharma | Zusammensetzungen verwendbar für die hemmung von rock und anderen kinasen |
US7361669B2 (en) * | 2003-01-02 | 2008-04-22 | Millennium Pharmaceuticals, Inc. | Compositions and method for inhibiting TGF-β |
TW200519106A (en) * | 2003-05-02 | 2005-06-16 | Novartis Ag | Organic compounds |
US7585881B2 (en) * | 2004-02-18 | 2009-09-08 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
EP1751133B1 (en) * | 2004-04-28 | 2010-04-14 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of rock and other protein kinases |
RU2423351C2 (ru) * | 2004-12-16 | 2011-07-10 | Вертекс Фармасьютикалз Инкорпорейтед | Пирид-2-оны, применимые как ингибиторы протеинкиназ семейства тес для лечения воспалительных, пролиферативных и иммунологически-опосредованных заболеваний |
KR101412943B1 (ko) * | 2006-06-28 | 2014-06-26 | 아스카 세이야쿠 가부시키가이샤 | 피리딜이소옥사졸 유도체 |
AU2007299261A1 (en) * | 2006-09-21 | 2008-03-27 | Novartis Ag | Pyrrole derivatives useful for the treatment of cytokine-mediated diseases |
EP2238134A2 (en) * | 2007-12-20 | 2010-10-13 | Novartis AG | Bis-thiazole derivatives, process for their preparation and their use as medicaments |
ES2437595T3 (es) * | 2007-12-20 | 2014-01-13 | Novartis Ag | Derivados de tiazol usados como inhibidores de la PI 3 quinasa |
WO2010093849A2 (en) * | 2009-02-13 | 2010-08-19 | Amgen Inc. | Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions |
RU2570907C2 (ru) * | 2013-10-21 | 2015-12-20 | Автономная Некоммерческая Организация "Научно-Исследовательский Центр Биотехнологии Антибиотиков И Других Биологически Активных Веществ "Биоан" | Производные 3-ациламинопиридин-2(1h)-она, применимые как ингибиторы серин-треониновой протеинкиназы gsk3b в качестве лекарственных препаратов для лечения диабета ii типа. |
JP7044789B2 (ja) | 2016-09-24 | 2022-03-30 | ワシントン・ユニバーシティ | Sarm1 nadアーゼ活性の阻害剤およびその使用 |
US20180251431A1 (en) * | 2016-12-09 | 2018-09-06 | Vertex Pharmaceuticals Incorporated | 1,3-substituted pyrazole compounds useful for reduction of very long chain fatty acid levels |
CA3108669A1 (en) * | 2018-06-07 | 2019-12-12 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 |
-
2021
- 2021-01-06 PE PE2022001414A patent/PE20230165A1/es unknown
- 2021-01-06 CR CR20220375A patent/CR20220375A/es unknown
- 2021-01-06 EP EP21703092.3A patent/EP4087838A1/en active Pending
- 2021-01-06 CA CA3163265A patent/CA3163265A1/en active Pending
- 2021-01-06 IL IL294507A patent/IL294507A/en unknown
- 2021-01-06 WO PCT/US2021/012333 patent/WO2021142006A1/en active Application Filing
- 2021-01-06 TW TW110100350A patent/TW202140437A/zh unknown
- 2021-01-06 CN CN202180019643.9A patent/CN115175900A/zh active Pending
- 2021-01-06 AU AU2021206651A patent/AU2021206651B2/en active Active
- 2021-01-06 BR BR112022013388A patent/BR112022013388A2/pt unknown
- 2021-01-06 KR KR1020227027204A patent/KR20220164471A/ko unknown
- 2021-01-06 MX MX2022008395A patent/MX2022008395A/es unknown
- 2021-01-06 JP JP2022541796A patent/JP7490781B2/ja active Active
- 2021-01-06 JO JOP/2022/0167A patent/JOP20220167A1/ar unknown
- 2021-08-17 US US17/404,523 patent/US20230008433A1/en active Pending
-
2022
- 2022-07-05 DO DO2022000141A patent/DOP2022000141A/es unknown
- 2022-07-05 CL CL2022001825A patent/CL2022001825A1/es unknown
- 2022-07-06 CO CONC2022/0009514A patent/CO2022009514A2/es unknown
- 2022-07-07 EC ECSENADI202253394A patent/ECSP22053394A/es unknown
-
2024
- 2024-02-06 AU AU2024200703A patent/AU2024200703A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2024200703A1 (en) | 2024-02-29 |
US20230008433A1 (en) | 2023-01-12 |
CN115175900A (zh) | 2022-10-11 |
JP7490781B2 (ja) | 2024-05-27 |
TW202140437A (zh) | 2021-11-01 |
JP2023510743A (ja) | 2023-03-15 |
CL2022001825A1 (es) | 2023-06-02 |
CO2022009514A2 (es) | 2022-10-21 |
AU2021206651B2 (en) | 2024-02-22 |
WO2021142006A1 (en) | 2021-07-15 |
ECSP22053394A (es) | 2022-11-30 |
MX2022008395A (es) | 2022-09-26 |
JOP20220167A1 (ar) | 2023-01-30 |
IL294507A (en) | 2022-09-01 |
DOP2022000141A (es) | 2022-10-16 |
EP4087838A1 (en) | 2022-11-16 |
AU2021206651A1 (en) | 2022-07-14 |
CA3163265A1 (en) | 2021-07-15 |
CR20220375A (es) | 2022-09-22 |
BR112022013388A2 (pt) | 2022-09-20 |
KR20220164471A (ko) | 2022-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20230165A1 (es) | Inhibidores de sarm1 | |
PE20191755A1 (es) | Derivados de pirazol como inhibidores de malt 1 | |
PE20200177A1 (es) | Inhibidores de pd-1/pd-l1 | |
AR057062A1 (es) | Moduladores de aminoquinolina y aminoquinazolina quinasa | |
AR055613A1 (es) | Formas cristalinas delta y epsilon de mesilato de imatinib | |
BRPI0515081B8 (pt) | composto, processo para a preparação de um sal de guanidino trifluormetilaroil amida, processo para a preparação de um fenil amino pirido pirimidina, composições farmacêuticas e processos para preparar (3,5-bis trifluormetil)-n-[4-metil-3-(4-piridin-3-il-pirimidin-2-ilamino)-fenil]-benzamida | |
CO2021007613A2 (es) | Formas cristalinas y formas de sal de un inhibidor de cinasa | |
AR055779A1 (es) | Proceso de preparacion de azoxistrobina y composicion que contiene al compuesto | |
AR059249A1 (es) | Compuesto amina trisustituido | |
BR112022002059A2 (pt) | Formas sólidas de um inibidor de hpk1 | |
BRPI0515594B8 (pt) | compostos inibidores da interação entre mdm2 e p53,composição farmacêutica, processo para a preparação desta composição farmacêutica, usos dos compostos, suas combinações e processo para a preparação destes compostos | |
BR112022017188A2 (pt) | Amidas heterocíclicas e seu uso para modulação de splicing | |
CO6160301A2 (es) | Preparacion solida que contiene alogliptina y clorhidrato de metformina | |
AR057109A1 (es) | Benzimidazoles sustituidos y metodos para usarlos como inhibidores de las quinasas asociadas con la tumorigenesis | |
PE20141996A1 (es) | Compuestos con actividad nematicida | |
ECSP109953A (es) | Derivados de piridazinona | |
ATE461923T1 (de) | Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren | |
PE20130008A1 (es) | Inhibidores de la replicacion del virus de la inmunodeficiencia humana | |
BR112021022758A2 (pt) | Compostos de 1-oxo-isoindolina-5-carboxamida substituídos, suas composições e métodos de tratamento com os mesmos | |
AR029301A1 (es) | Compuestos derivados de biarilo, metodos para su preparacion composiciones que los contienen, su uso como agonistas en receptores beta-adreno-receptores atipicos | |
BRPI0607019A2 (pt) | compostos que inibem a atividade de beta -secretase e métodos de uso dos mesmos | |
PE20210373A1 (es) | Compuestos de pirimidina y composiciones farmaceuticas para prevenir o tratar canceres que incluyen los mismos | |
AR080596A1 (es) | Compuestos alquilamido y composiciones farmaceuticas | |
BRPI0408353A (pt) | composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto | |
EA201000101A1 (ru) | Производные пиримидина 934 |